Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Strategic property basis allocation focusing on land and building depreciation enhances real estate value while maximizing tax benefits for investors.
Weaver's Jeremy Winkler and Selina McUmber discuss insights and trends from the 2024 NCREIF conference on real estate, valuations and global future-shaping factors.
Discover how Property Assessed Clean Energy (PACE) financing drives business growth in this episode of Weaver: Beyond the Numbers, Location Cubed.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
Explore the nuances of valuations for real estate assets, and its cadence, challenges and strategies.
Uncover realty insights in Weaver: Beyond the Numbers, Location Cubed, following a NYC office tower auction and its potential implications on urban development.
Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.
Common scenarios VC managers face as they prepare their valuations for their financial statement audit and tips for approaching the valuation analysis.
Tyler Ridley joined this episode of Weaver: Beyond the Numbers podcast with Weaver hosts Howard Altshuler and Rob Nowak to discuss the rebound and current financial state of the biopharma and med tech industries.